All Relations between Stroke and glp-1

Publication Sentence Publish Date Extraction Date Species
Jae-Han Jeo. SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes. Diabetes & metabolism journal. vol 48. issue 2. 2024-04-01. PMID:38556704. sglt2 inhibitors and glp-1 agonists: a beacon of hope for stroke prevention in diabetes. 2024-04-01 2024-04-03 Not clear
Jun-Jun Yeh, Chih-Chien Li, Chang-Wen Tan, Chia-Hsun Li, Tung-Han Tsai, Chia-Hung Ka. Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes. Biomedicines. vol 12. issue 3. 2024-03-28. PMID:38540106. the time between the diagnoses of dm and the initial use of the glp-1 ra among the stroke subcohort (<2000 days) was shorter than that of the heart disease subcohort (>2000 days) (all 2024-03-28 2024-03-30 Not clear
Maria-Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, Diana Aguiar de Sousa, Mira Katan, Lina Palaiodimou, Aristeidis H Katsanos, Ioanna Koutroulou, Vaia Lambadiari, Robin Lemmens, Sotirios Giannopoulos, Andrei V Alexandrov, Gerasimos Siasos, Georgios Tsivgouli. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis. European stroke journal. 2024-02-24. PMID:38400569. risk of major adverse cardiovascular events and stroke associated with treatment with glp-1 or the dual gip/glp-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis. 2024-02-24 2024-02-26 Not clear
Christopher F Bladin, Ngai Wah Cheung, Helen M Dewey, Leonid Churilov, Sandy Middleton, Vincent Thijs, Elif Ekinci, Christopher R Levi, Richard Lindley, Geoffrey A Donnan, Mark W Parsons, Atte Meretoja, Marjaana Tiainen, Philip M C Choi, Dennis Cordato, Helen Brown, Bruce C V Campbell, Stephen M Davis, Geoffrey Cloud, Rohan Grimley, Matthew Lee-Archer, Darshan Ghia, Lauren Sanders, Romesh Markus, Claire Muller, Patrick Salvaris, Teddy Wu, John Fin. Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial. Stroke. vol 54. issue 12. 2023-11-27. PMID:38011235. we investigated whether exenatide, a glp-1 (glucagon-like peptide-1) receptor agonist, would improve stroke outcomes, and control poststroke hyperglycemia with minimal hypoglycemia. 2023-11-27 2023-11-29 Not clear
André J Schee. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies. Diabetes & metabolism. 2023-09-07. PMID:37678760. do sglt2 inhibitors and glp-1 receptor agonists modulate differently the risk of stroke ? 2023-09-07 2023-10-07 Not clear
John E Anderson, Javed Butler, Andrei V Alexandro. Reducing Ischemic Stroke in Diabetes: The Role of GLP-1 RAs. The Journal of family practice. vol 72. issue 6 Suppl. 2023-08-07. PMID:37549420. glucagon-like peptide-1 receptor agonists (glp-1 ras) lower the risk of ischemic stroke through beneficial effects on traditional stroke risk factors such as hyperglycemia, hypertension, and dyslipidemia. 2023-08-07 2023-08-14 Not clear
John E Anderson, Javed Butler, Andrei V Alexandro. Reducing Ischemic Stroke in Diabetes: The Role of GLP-1 RAs. The Journal of family practice. vol 72. issue 6 Suppl. 2023-08-07. PMID:37549420. the use of glp-1 ras, in addition to non-pharmacologic and pharmacologic management of traditional stroke risk factors, is a key component of complex therapy for ischemic stroke risk reduction. 2023-08-07 2023-08-14 Not clear
David M Williams, Michael Atkinson, Marc Evan. Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues? Stroke. 2023-03-02. PMID:36861476. stroke prevention and treatment in people with type 2 diabetes: is there a role for glp-1 (glucagon-like peptide-1) analogues? 2023-03-02 2023-08-14 Not clear
Jinjing Wei, Bing Yang, Ruxin Wang, Haowen Ye, Ying Wang, Lihong Wang, Xiaofang Zhan. Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis. Frontiers in endocrinology. vol 13. 2022-12-22. PMID:36545339. risk of stroke and retinopathy during glp-1 receptor agonist cardiovascular outcome trials: an eight rcts meta-analysis. 2022-12-22 2023-08-14 Not clear
Jiaxi Li, Cheng Ji, Wen Zhang, Linyan Lan, Weihong G. Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. Journal of diabetes and its complications. vol 37. issue 1. 2022-12-03. PMID:36462459. the effects of glucagon-like peptide-1 (glp-1) agonists, sodium-glucose cotransporter-2 (sglt-2) inhibitors, and dipeptidyl peptidase-4 (dpp-4) inhibitors on stroke risk were evaluated in published rcts. 2022-12-03 2023-08-14 Not clear
Darren K McGuire, David D'Alessio, Stephen J Nicholls, Steven E Nissen, Jeffrey S Riesmeyer, Imre Pavo, Shanthi Sethuraman, Cory R Heilmann, John J Kaiser, Govinda J Weerakkod. Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. Cardiovascular diabetology. vol 21. issue 1. 2022-08-24. PMID:36002856. to determine the efficacy margin for the hazard ratio, tirzepatide versus dulaglutide, for the composite cv outcome of death, myocardial infarction, or stroke (mace-3), which is required to claim superiority versus an imputed placebo, the lower bound of efficacy of dulaglutide compared with placebo was estimated using a hierarchical bayesian meta-analysis of placebo-controlled cvots of glp-1 ras. 2022-08-24 2023-08-14 Not clear
W David Strain, Ofir Frenkel, Martin A James, Lawrence A Leiter, Søren Rasmussen, Peter M Rothwell, Maria Sejersten Ripa, Thomas C Truelsen, Mansoor Husai. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022-05-18. PMID:35582947. glp-1 ra (glucagon-like peptide-1 receptor agonists), including semaglutide, may reduce stroke risk in people with type 2 diabetes. 2022-05-18 2023-08-13 Not clear
Zaynab Ahmad Mouhammad, Rupali Vohra, Anna Horwitz, Anna-Sophie Thein, Jens Rovelt, Barbara Cvenkel, Pete A Williams, Augusto Azuara-Blanco, Miriam Kolk. Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma? Frontiers in neuroscience. vol 16. 2022-03-10. PMID:35264926. glp-1 receptor (glp-1r) agonists have shown neuroprotective effects in preclinical and clinical studies on neurodegenerative diseases in both the brain (e.g., alzheimer's disease, parkinson's disease, stroke and diabetic neuropathy) and the eye (e.g., diabetic retinopathy and amd). 2022-03-10 2023-08-13 Not clear
Ronald M Goldenberg, Alice Y Y Cheng, Tess Fitzpatrick, Jeremy D Gilbert, Subodh Verma, Julia J Hopya. Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. Stroke. 2022-03-09. PMID:35259929. benefits of glp-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 diabetes: a call to action for neurologists. 2022-03-09 2023-08-13 Not clear
Szymon Jonik, Michał Marchel, Marcin Grabowski, Grzegorz Opolski, Tomasz Mazure. Gastrointestinal Incretins-Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease-State of the Art. Biology. vol 11. issue 2. 2022-02-25. PMID:35205155. furthermore, four large clinical trials showed a significant reduction in composite of cv death, mi, and stroke in long-term follow-up using glp-1 analogs for dm 2 patients: liraglutide in leader, semaglutide in sustain-6, dulaglutide in rewind and albiglutide in harmony. 2022-02-25 2023-08-13 human
Bertram Pitt, Gabriel Steg, Lawrence A Leiter, Deepak L Bhat. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular drugs and therapy. 2021-11-09. PMID:34750713. this paper will briefly compare the effect of sglt2is and glp-1 ras to that of the sglt1/2 inhibitor sotagliflozin on the incidence of myocardial infarction (mi) and stroke in patients with t2dm and further postulate mechanisms to account for these findings. 2021-11-09 2023-08-13 Not clear
Mustafa Kılıçkap, Meral Kayıkçıoğlu, Lale Tokgözoğl. An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. Anatolian journal of cardiology. vol 25. issue 2. 2021-10-15. PMID:33583813. a systematic pubmed search was conducted for cv outcome studies of glp-1 receptor agonists and sglt-2 inhibitors with the main outcome of three-point major adverse cardiovascular events (mace), which is the composite of cv death, non-fatal myocardial infarction (mi), and non-fatal stroke. 2021-10-15 2023-08-13 human
Huinan Zhang, Yunhan Liu, Liusiyuan Cheng, Xue Ma, Xiaoxing Lu. Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R. Brain research bulletin. vol 169. 2021-10-07. PMID:33197537. glucagon-like peptide-1 (glp-1) receptor (glp-1r) agonist exendin-4 (ex-4), a drug that has been used in the clinical treatment of type 2 diabetes mellitus, also confers a neuroprotective effect against stroke. 2021-10-07 2023-08-13 mouse
Huinan Zhang, Yunhan Liu, Liusiyuan Cheng, Xue Ma, Xiaoxing Lu. Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R. Brain research bulletin. vol 169. 2021-10-07. PMID:33197537. although glp-1 analogs were reported to induce sustained insulin secretion and glucose tolerance improved after cessation of treatment, no study has revealed whether ex-4 exerts sustained neuroprotection against stroke and the underlying mechanism after treatment cessation. 2021-10-07 2023-08-13 mouse
Tina K Thethi, Anika Bilal, Richard E Pratle. Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes spectrum : a publication of the American Diabetes Association. vol 34. issue 3. 2021-09-14. PMID:34511847. the glp-1 receptor agonists liraglutide, dulaglutide, and injectable semaglutide demonstrated a significant cv benefit in these trials and now have indications to reduce the risk of major adverse cv events, including cv death, myocardial infarction, and stroke in adult patients with type 2 diabetes and established cardiovascular disease or high cv risk (dulaglutide). 2021-09-14 2023-08-13 Not clear